SP-002

Stamford Pharmaceuticals, Inc. · Phase 2 active Small molecule

At a glance

Generic name	SP-002
Sponsor	Stamford Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SP-002 CI brief — competitive landscape report
SP-002 updates RSS · CI watch RSS
Stamford Pharmaceuticals, Inc. portfolio CI